Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cord blood stem cells tested in stroke patients – early safety check

NCT ID NCT03186456

Disease control Sponsor: Sclnow Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether stem cells from donated umbilical cords are safe for people who recently had a stroke. Forty participants will receive three monthly infusions of the cells along with standard aspirin therapy. The study is currently on hold, and its main goal is to monitor for side effects, not to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
human umbilical cord-derived mesenchymal stem cells
What this could lead to
If it works, this could point toward a new way to help people recover from stroke by reducing brain damage.
What could go wrong
This is a very early, small trial (Phase 1, 40 people) that is currently suspended. It only tests safety, not whether it truly works, and stem cell treatments carry risks like infection or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient within 2 weeks onset of symptoms. * Symptoms and signs of clinically definite acute cerebral infarction patients. * CT/MRI prove the Oxfordshire Community Stroke Project (OCSP) as Total Anterior circulation infarct (TACI), Partial Anterior circulation infarct (PACI), Posterior Anterior circulation infarct (POCI), or obvious neurological deficit lacunar infarction patient. * Signed informed consent after understanding all possible benefits and harm. Exclusion Criteria: * allergic to basic drug * with progressive stroke, transient ischemia attach, cerebral infarction with posterior cerebral hemorrhage, and cerebral arteritis. * tumor, injury, and parasites caused cerebral embolism * rheumatic heart disease, coronary heart disease, and other atrial fibrillation combined heart disease caused cerebral embolism * subject is processing thrombolytic therapy * subject is pregnancy and of childbearing potential or breast feeding * participate in any other clinical trial in last 3 months * bleeding tendency patient; severe bleeding tendency in last 3 month * with gastric duodenal ulcer * participants with severe liver and kidney, hematopoietic, and metabolic diseases; Or with liver and kidney function examination abnormal * participants are intolerance with Aspirin Enteric-coated Tablets, or need other antiplatelet drugs * participants: alcoholism, drug addicted, or other situations may complicated the results * under other therapy that possibly influence MSC security or efficacy * investigator supposes not suitable to participate this clinical trail

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Inner Mongolia International Mongolian Hospital

    Hohhot, Inner Mongolia, 010065, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.